Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Cross Asset Strategy

<ul>
<li>Now that Lee Jae-Myung has become new South Korean President, the uncertainty revolving who will lead South Korea in the next five years is now over.</li>
<li>In this insight, we discuss four investment themes (related to Lee Jae-Myung becoming the new South Korean President) that could outperform the market for the remainder of 2025.</li>
<li>The four investment themes include Korean Holdcos/Quasi Holdcos, Korean Cultural Contents, Securities, and SK Group Companies.</li>
</ul>


Now that Lee Jae-Myung has become new South Korean President, the uncertainty revolving who will lead South Korea in the next five years is now over.
In this insight, we discuss four investment themes (related to Lee Jae-Myung becoming the new South Korean President) that could outperform the market for the remainder of 2025.
The four investment themes include Korean Holdcos/Quasi Holdcos, Korean Cultural Contents, Securities, and SK Group Companies.


Lee Jae-Myung Becomes the New South Korean President - Four Investment Themes That Could Outperform

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hk-inno-n-corp" target="_blank" data-smartkarma-citation="entities:33522:1" rel="noopener">HK inno.N (195940 KS)</a> reported 1Q26 result, with all key parameters showing improvement compared to year-ago period. Continued strong sales of mainstay prescription drug business remained the key driver.</li>
<li>Significant improvement in profitability, driven by double-digit growth in major prescription drug products, along with strong growth in K-CAB China royalty, is the key highlight of 1Q26 result.</li>
<li>HK inno is expected to maintain growth momentum, with U.S. approval of K-CAB being the next catalyst. The company is strengthening prescription drug business and innovative drug pipeline beyond K-CAB.</li>
</ul>



HK inno.N (195940 KS) reported 1Q26 result, with all key parameters showing improvement compared to year-ago period. Continued strong sales of mainstay prescription drug business remained the key driver.
Significant improvement in profitability, driven by double-digit growth in major prescription drug products, along with strong growth in K-CAB China royalty, is the key highlight of 1Q26 result.
HK inno is expected to maintain growth momentum, with U.S. approval of K-CAB being the next catalyst. The company is strengthening prescription drug business and innovative drug pipeline beyond K-CAB.


HK Inno.N (195940 KS): Modest Show In 1Q26; All Eyes on Maiden US Approval; Strengthening Pipeline

<ul>
<li>Three main reasons why SK Inc is our high conviction in 2026 include mandatory cancellation of treasury shares, deep discount to NAV, and the end of divorce for Chairman Chey. </li>
<li>SK Inc has 17.98 million shares in treasury, representing 24.8% of outstanding shares. Among the stocks included in KOSPI200, this is one of the highest percentage of treasury shares.</li>
<li>Our NAV valuation analysis suggests NAV of 28 trillion won or NAV per share of 386,469 won. This represents a 46% upside to its current price.</li>
</ul>


Three main reasons why SK Inc is our high conviction in 2026 include mandatory cancellation of treasury shares, deep discount to NAV, and the end of divorce for Chairman Chey. 
SK Inc has 17.98 million shares in treasury, representing 24.8% of outstanding shares. Among the stocks included in KOSPI200, this is one of the highest percentage of treasury shares.
Our NAV valuation analysis suggests NAV of 28 trillion won or NAV per share of 386,469 won. This represents a 46% upside to its current price.


Event-Driven

<ul>
<li><em><strong>SK Inc (034730 KS) announced that it plans to sell about 1.25 trillion won worth of its stake (13.94%) in SK Biopharmaceuticals (326030 KS) through a PRS contract.</strong></em></li>
<li>SK Inc plans to sell 10.917 million shares of SK Biopharm on 30 March 2026. Selling price for SK Biopharm is 114,500 won.</li>
<li>We believe that this PRS transaction is likely to positively impact SK Inc and SKC. However, it should have a slight negative impact on SK Biopharm.</li>
</ul>


SK Inc (034730 KS) announced that it plans to sell about 1.25 trillion won worth of its stake (13.94%) in SK Biopharmaceuticals (326030 KS) through a PRS contract.
SK Inc plans to sell 10.917 million shares of SK Biopharm on 30 March 2026. Selling price for SK Biopharm is 114,500 won.
We believe that this PRS transaction is likely to positively impact SK Inc and SKC. However, it should have a slight negative impact on SK Biopharm.


SK Inc: Selling 1.25 Trillion Won Worth of SK Biopharm Through a PRS Contract

Thematic (Sector/Industry)

<ul>
<li>Sino Biopharmaceutical’s NDA for bispecific ADC, TQB2102, has been accepted by NMPA for breast cancer. CHMP recommended approval of Impact Therapeutics’ Sepalna for epithelial ovarian, fallopian tube, and peritoneal cancers.</li>
<li>FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque psoriasis. Daiichi Sankyo announced positive results from the Phase 3 trial evaluating Enhertu as a first-line treatment of NSCLC.</li>
<li>SK Biopharmaceuticals has signed a license and equity investment agreement with 1ST Biotherapeutics to secure global exclusive development and commercialization rights for a new drug candidate for Parkinson's disease.</li>
</ul>


Sino Biopharmaceutical’s NDA for bispecific ADC, TQB2102, has been accepted by NMPA for breast cancer. CHMP recommended approval of Impact Therapeutics’ Sepalna for epithelial ovarian, fallopian tube, and peritoneal cancers.
FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque psoriasis. Daiichi Sankyo announced positive results from the Phase 3 trial evaluating Enhertu as a first-line treatment of NSCLC.
SK Biopharmaceuticals has signed a license and equity investment agreement with 1ST Biotherapeutics to secure global exclusive development and commercialization rights for a new drug candidate for Parkinson's disease.


APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm

South Korea

SK Biopharmaceuticals Co., Ltd. researches and develops new drugs. The Company develops and markets brain disorders treatment drugs, central nervous system disorders treatment drugs, and other products. SK Biopharmaceuticals markets its products worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

SK Biopharmaceuticals (326030 KS)

Lee Jae-Myung Becomes the New South Korean President - Four Investment Themes That Could Outperform

In this insight, we discuss four investment themes (related to Lee Jae-Myung becoming the new South Korean President) that could outperform the...

Douglas Kim

HK Inno.N (195940 KS): Modest Show In 1Q26; All Eyes on Maiden US Approval; Strengthening Pipeline

HK inno reports 1Q26 result, with key parameters showing improvement compared to year-ago period. The company is expected to maintain momentum,...

Tina Banerjee

2026 High Conviction Idea: SK Inc

SK Inc (034730 KS) just announced that it will cancel about 20% of its outstanding shares, representing 4.8 trillion won ($3.3 billion). This is...

Douglas Kim

SK Inc: Selling 1.25 Trillion Won Worth of SK Biopharm Through a PRS Contract

SK Inc (034730 KS) announced that it plans to sell about 1.25 trillion won worth of its stake (13.94%) in SK Biopharmaceuticals (326030 KS) through...

Douglas Kim

APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm

NMPA accepted Sino Bio’s NDA for bispecific ADC drug candidate. FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Lee Jae-Myung Becomes the New South Korean President - Four Investment Themes That Could Outperform

In this insight, we discuss four investment themes (related to Lee Jae-Myung becoming the new South Korean President) that could outperform the...

Douglas Kim

HK Inno.N (195940 KS): Modest Show In 1Q26; All Eyes on Maiden US Approval; Strengthening Pipeline

​HK inno reports 1Q26 result, with key parameters showing improvement compared to year-ago period. The company is expected to maintain momentum,...

Tina Banerjee

2026 High Conviction Idea: SK Inc

SK Inc (034730 KS) just announced that it will cancel about 20% of its outstanding shares, representing 4.8 trillion won ($3.3 billion). This is...

Douglas Kim

SK Inc: Selling 1.25 Trillion Won Worth of SK Biopharm Through a PRS Contract

SK Inc (034730 KS) announced that it plans to sell about 1.25 trillion won worth of its stake (13.94%) in SK Biopharmaceuticals (326030 KS) through...

Douglas Kim

APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm

NMPA accepted Sino Bio’s NDA for bispecific ADC drug candidate. FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque...

Tina Banerjee

HK inno reports 1Q26 result, with key parameters showing improvement compared to year-ago period. The company is expected to maintain momentum,...